Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96


Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer.

Zhou K, Zhou J, Huang J, Zhang N, Bai L, Yang Y, Li Q.

Lung Cancer. 2019 Apr;130:1-4. doi: 10.1016/j.lungcan.2019.01.019. Epub 2019 Feb 1.


First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.

Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV; IMpower133 Study Group.

N Engl J Med. 2018 Dec 6;379(23):2220-2229. doi: 10.1056/NEJMoa1809064. Epub 2018 Sep 25.


Cost-effectiveness analysis of sensitive relapsed small-cell lung cancer based on JCOG0605 trial.

Zhou K, Wen F, Zhang P, Zhou J, Zheng H, Sun L, Li Q.

Clin Transl Oncol. 2018 Jun;20(6):768-774. doi: 10.1007/s12094-017-1787-y. Epub 2017 Nov 2.


Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC).

Ondhia U, Conter HJ, Owen S, Zhou A, Nam J, Singh S, Abdulla A, Chu P, Felizzi F, Paracha N, Sangha R.

J Med Econ. 2019 Mar 5:1-13. doi: 10.1080/13696998.2019.1590842. [Epub ahead of print]


Cost-Effectiveness of Thoracic Radiation Therapy for Extensive-Stage Small Cell Lung Cancer Using Evidence From the Chest Radiotherapy Extensive-Stage Small Cell Lung Cancer Trial (CREST).

Patrice GI, Lester-Coll NH, Yu JB, Amdahl J, Delea TE, Patrice SJ.

Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):97-106. doi: 10.1016/j.ijrobp.2017.08.041. Epub 2017 Sep 4.


Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.

Wu B, Chen H, Shen J, Ye M.

Clin Ther. 2011 Oct;33(10):1446-55. doi: 10.1016/j.clinthera.2011.09.016. Epub 2011 Oct 11.


Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.

Reck M, Luft A, Szczesna A, Havel L, Kim SW, Akerley W, Pietanza MC, Wu YL, Zielinski C, Thomas M, Felip E, Gold K, Horn L, Aerts J, Nakagawa K, Lorigan P, Pieters A, Kong Sanchez T, Fairchild J, Spigel D.

J Clin Oncol. 2016 Nov 1;34(31):3740-3748. doi: 10.1200/JCO.2016.67.6601.


Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.

Mistry R, May JR, Suri G, Young K, Brixner D, Oderda G, Biskupiak J, Tang D, Bhattacharyya S, Mishra D, Bhattacharyya D, Dalal AA.

J Manag Care Spec Pharm. 2018 Jun;24(6):514-523. doi: 10.18553/jmcp.2018.24.6.514.


Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States.

Zhou ZY, Mutebi A, Han S, Bensimon AG, Louise Ricculli M, Xie J, Dalal A, Culver K.

J Med Econ. 2018 Jun;21(6):577-586. doi: 10.1080/13696998.2018.1443111. Epub 2018 Mar 12.


The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.

Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.


Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.

Tappenden P, Jones R, Paisley S, Carroll C.

Health Technol Assess. 2007 Mar;11(12):1-128, iii-iv. Review.


Carboplatin plus pemetrexed offers superior cost-effectiveness compared to pemetrexed in patients with advanced non-small cell lung cancer and performance status 2.

Schluckebier L, Garay OU, Zukin M, Ferreira CG.

Lung Cancer. 2015 Sep;89(3):274-9. doi: 10.1016/j.lungcan.2015.06.015. Epub 2015 Jun 22.


First-Line Atezolizumab OK'd for SCLC.

[No authors listed]

Cancer Discov. 2019 Mar 25. doi: 10.1158/2159-8290.CD-NB2019-042. [Epub ahead of print]


Economic outcomes of maintenance gefitinib for locally advanced/metastatic non-small-cell lung cancer with unknown EGFR mutations: a semi-Markov model analysis.

Zeng X, Li J, Peng L, Wang Y, Tan C, Chen G, Wan X, Lu Q, Yi L.

PLoS One. 2014 Feb 20;9(2):e88881. doi: 10.1371/journal.pone.0088881. eCollection 2014.


Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.

Brown T, Pilkington G, Bagust A, Boland A, Oyee J, Tudur-Smith C, Blundell M, Lai M, Martin Saborido C, Greenhalgh J, Dundar Y, Dickson R.

Health Technol Assess. 2013 Jul;17(31):1-278. doi: 10.3310/hta17310. Review. Erratum in: Health Technol Assess. 2015 May;17(31):281-2.


The clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation.

Loveman E, Jones J, Hartwell D, Bird A, Harris P, Welch K, Clegg A.

Health Technol Assess. 2010 Mar;14(19):1-204. doi: 10.3310/hta14190. Review.


Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.

Chouaid C, Bensimon L, Clay E, Millier A, Levy-Bachelot L, Huang M, Levy P.

Lung Cancer. 2019 Jan;127:44-52. doi: 10.1016/j.lungcan.2018.11.008. Epub 2018 Nov 23.

Supplemental Content

Support Center